Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carfilzomib + CC-92480 + Dexamethasone |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CC-92480 | CELMoD CC92480|CC 92480|Mezigdomide|BMS-986348|BMS986348|BMS 986348 | CC-92480 binds to and modulates activity of the ubiquitin E3 ligase complex member Cereblon (CRBN), which may induce ubiquitination and degradation of transcription factors in T-lymphocytes, resulting in immune system activation (Blood (2019) 134 (Supplement_1): 1812, PMID: 32130004). | ||
| Carfilzomib | Kyprolis | PR-171 | Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). | |
| Dexamethasone | Adexone | Desametasone |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05552976 | Phase III | Carfilzomib + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone | A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2) | Recruiting | USA | ROU | NOR | NLD | ITA | ISR | HUN | GRC | GBR | ESP | DNK | DEU | CAN | BRA | BGR | AUT | AUS | ARG | 9 |
| NCT03989414 | Phase Ib/II | Bortezomib + CC-92480 + Dexamethasone CC-92480 + Daratumumab + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone | A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | Active, not recruiting | USA | ITA | GRC | FRA | ESP | DNK | DEU | CZE | CAN | 0 |
CKB BOOST